Back to search results

Observational Study of EUS-Guided Ablation for Pancreatic and Other GI Lesions

This study is an observational registry that collects information on adults (18 years or older) who are already receiving endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic, gastrointestinal, or liver lesions as part of their regular medical care. This means the study will not change your treatment. Researchers will look at how the size of your lesion changes over 1, 3, and 6 months after ablation. They will also track overall survival, side effects, and patient-reported symptoms. The study aims to enroll 50 participants, but its current recruitment status is unclear.

Study design
This is a single-center, observational registry study planning to enroll 50 adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track changes in lesion size for 6 months after ablation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07625189

EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry

Recruiting
Not specifiedAges 18+Observational
West Virginia University
~50 participants
Updated 2026-06-04 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change From Baseline to 1 Month in Target Lesion Size
Measured over Baseline to 1 month
+5 more outcomes measured

Conditions

RFA
Microwave Ablation
Pancreatic Lesion
Gastrointestinal Lesions
Ablation Techniques

Explore related trials

Gastrointestinal sensationHepatobiliary LesionPancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type

Where it's being run

1 sites across 1 states
West Virginia1

Study leadership

  • Shailendra Singh, MD · PRINCIPAL_INVESTIGATOR · West Virginia University

Who to contact

Zim Warda Hasan
[email protected]
364-203-1900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults ≥ 18 years of age.
Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.
At least one clinically identified target lesion for which RFA or MWA is performed.

Exclusion

In the judgment of the treating clinician, inclusion in the registry would not be appropriate
The individual is expected to be unable to complete routine clinical follow-up.

What this trial measures

  • Change From Baseline to 1 Month in Target Lesion SizeBaseline to 1 month

    Change in tumor size (cm) from baseline to 1 month, assessed by imaging.

  • Change From Baseline to 3 Months in Target Lesion SizeBaseline to 3 months

    Change in tumor size (cm) from baseline to 3 months, assessed by imaging.

  • Change From Baseline to 6 Months in Target Lesion SizeBaseline to 6 months

    Change in tumor size (cm) from baseline to 6 months, assessed by imaging.

  • Change From Baseline to 12 Months in Target Lesion SizeBaseline to 12 months

    Change in tumor size (cm) from baseline to 12 months, assessed by imaging.

  • Overall SurvivalFrom ablation to death or last follow-up, assessed up to 1 year

    Overall survival defined as the time from ablation to death from any cause. Participants still alive will be censored at last known follow-up.

  • Overall SurvivalFrom ablation to death or last follow-up, assessed up to 3 year

    Overall survival defined as the time from ablation to death from any cause. Participants still alive will be censored at last known follow-up.